GSK has teamed up with two research organisations in the UK to explore a possible link between its shingles vaccine, Shingrix, and a reduced risk of dementia. The tantalising hypothesis – drawn from ...
GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to grab a slice of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback